{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T14:28:36Z","timestamp":1771079316758,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2022JJ70099"],"award-info":[{"award-number":["2022JJ70099"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hunan Provincial People's Hospital Doctoral Fund Project","award":["BSJJ202106"],"award-info":[{"award-number":["BSJJ202106"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The basic helix-loop-helix family member e41 (BHLHE41) is frequently dysregulated in tumors and plays a crucial role in malignant progression of various cancers. Nevertheless, its specific function and underlying mechanism in bladder cancer (BCa) remain largely unexplored.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The expression levels of BHLHE41 in BCa tissues and cells were examined by qRT-PCR and western blot assays. BCa cells stably knocking down or overexpressing BHLHE41 were constructed through lentivirus infection. The changes of cell proliferation, cell cycle distribution, migration, and invasion were detected by CCK-8, flow cytometry, wound healing, transwell invasion assays, respectively. The expression levels of related proteins were detected by western blot assay. The interaction between BHLHE41 and PYCR1 was explored by co-immunoprecipitation analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In this study, we found that BHLHE41 was lowly expressed in bladder cancer tissues and cell lines, and lower expression of BHLHE41 was associated with poor overall survival in bladder cancer patients. Functionally, by manipulating the expression of BHLHE41, we demonstrated that overexpression of BHLHE41 significantly retarded cell proliferation, migration, invasion, and induced cell cycle arrest in bladder cancer through various in <jats:italic>vitro<\/jats:italic> and in <jats:italic>vivo<\/jats:italic> experiments, while silence of BHLHE41 caused the opposite effect. Mechanistically, we showed that BHLHE41 directly interacted with PYCR1, decreased its stability and resulted in the ubiquitination and degradation of PYCR1, thus inactivating PI3K\/AKT signaling pathway. Rescue experiments showed that the effects induced by BHLHE41 overexpression could be attenuated by further upregulating PYCR1.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>BHLHE41 might be a useful prognostic biomarker and a tumor suppressor in bladder cancer. The BHLHE41\/PYCR1\/PI3K\/AKT axis might be a potential therapeutic target for bladder cancer intervention.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40001-024-01889-2","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T04:01:54Z","timestamp":1716955314000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["BHLHE41 inhibits bladder cancer progression via regulation of PYCR1 stability and thus inactivating PI3K\/AKT signaling pathway"],"prefix":"10.1186","volume":"29","author":[{"given":"Shuai","family":"Xiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongbao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,29]]},"reference":[{"issue":"3","key":"1889_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"19","key":"1889_CR2","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis AT, et al. Bladder cancer: a review. JAMA. 2020;324(19):1980\u201391.","journal-title":"JAMA"},{"key":"1889_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13030512","author":"B Barone","year":"2023","unstructured":"Barone B, et al. Bladder cancer and risk factors: data from a multi-institutional long-term analysis on cardiovascular disease and cancer incidence. J Pers Med. 2023. https:\/\/doi.org\/10.3390\/jpm13030512.","journal-title":"J Pers Med"},{"issue":"2","key":"1889_CR4","doi-asserted-by":"publisher","first-page":"e166","DOI":"10.1016\/j.clgc.2021.12.005","volume":"20","author":"M Ferro","year":"2022","unstructured":"Ferro M, et al. Impact of age on outcomes of patients with pure carcinoma in situ of the bladder: multi-institutional cohort analysis. Clin Genitourin Cancer. 2022;20(2):e166\u201372.","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"1889_CR5","doi-asserted-by":"publisher","first-page":"783","DOI":"10.6004\/jnccn.2020.7585","volume":"18","author":"ER Kessler","year":"2020","unstructured":"Kessler ER, et al. Treating elderly patients with muscle-invasive bladder cancer. J Natl Compr Canc Netw. 2020;18(6):783\u201390.","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"1889_CR6","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.euf.2020.01.007","volume":"6","author":"G Gakis","year":"2020","unstructured":"Gakis G. Management of muscle-invasive bladder cancer in the 2020s: challenges and perspectives. Eur Urol Focus. 2020;6(4):632\u20138.","journal-title":"Eur Urol Focus"},{"issue":"1","key":"1889_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"J Alfred Witjes","year":"2024","unstructured":"Alfred Witjes J, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur Urol. 2024;85(1):17\u201331.","journal-title":"Eur Urol"},{"key":"1889_CR8","doi-asserted-by":"publisher","first-page":"17022","DOI":"10.1038\/nrdp.2017.22","volume":"3","author":"O Sanli","year":"2017","unstructured":"Sanli O, et al. Bladder cancer. Nat Rev Dis Primers. 2017;3:17022.","journal-title":"Nat Rev Dis Primers"},{"key":"1889_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030566","author":"J Esteban-Villarrubia","year":"2023","unstructured":"Esteban-Villarrubia J, et al. Current and future landscape of perioperative treatment for muscle-invasive bladder cancer. Cancers. 2023. https:\/\/doi.org\/10.3390\/cancers15030566.","journal-title":"Cancers"},{"key":"1889_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102142","volume":"93","author":"M Rey-C\u00e1rdenas","year":"2021","unstructured":"Rey-C\u00e1rdenas M, et al. Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: what to expect in the near future. Cancer Treat Rev. 2021;93: 102142.","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"1889_CR11","doi-asserted-by":"publisher","first-page":"490.e13","DOI":"10.1016\/j.urolonc.2022.05.016","volume":"40","author":"M Ferro","year":"2022","unstructured":"Ferro M, et al. Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer. Urol Oncol. 2022;40(11):490.e13-490.e20.","journal-title":"Urol Oncol"},{"key":"1889_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.canlet.2021.02.010","volume":"505","author":"S Liu","year":"2021","unstructured":"Liu S, Chen X, Lin T. Lymphatic metastasis of bladder cancer: molecular mechanisms, diagnosis and targeted therapy. Cancer Lett. 2021;505:13\u201323.","journal-title":"Cancer Lett"},{"issue":"5","key":"1889_CR13","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41585-022-00578-1","volume":"19","author":"JY Teoh","year":"2022","unstructured":"Teoh JY, et al. Recurrence mechanisms of non-muscle-invasive bladder cancer\u2014a clinical perspective. Nat Rev Urol. 2022;19(5):280\u201394.","journal-title":"Nat Rev Urol"},{"issue":"5","key":"1889_CR14","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ccell.2021.04.012","volume":"39","author":"M Knowles","year":"2021","unstructured":"Knowles M, et al. Metastatic urothelial carcinoma. Cancer Cell. 2021;39(5):583\u20135.","journal-title":"Cancer Cell"},{"issue":"19","key":"1889_CR15","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2018101233","volume":"38","author":"R Rauschmeier","year":"2019","unstructured":"Rauschmeier R, et al. Bhlhe40 and Bhlhe41 transcription factors regulate alveolar macrophage self-renewal and identity. Embo j. 2019;38(19): e101233.","journal-title":"Embo j"},{"issue":"7","key":"1889_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110386","volume":"38","author":"H Hong","year":"2022","unstructured":"Hong H, et al. Postnatal regulation of B-1a cell development and survival by the CIC-PER2-BHLHE41 axis. Cell Rep. 2022;38(7): 110386.","journal-title":"Cell Rep"},{"issue":"4","key":"1889_CR17","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/ni.3694","volume":"18","author":"T Kreslavsky","year":"2017","unstructured":"Kreslavsky T, et al. Essential role for the transcription factor Bhlhe41 in regulating the development, self-renewal and BCR repertoire of B-1a cells. Nat Immunol. 2017;18(4):442\u201355.","journal-title":"Nat Immunol"},{"issue":"4","key":"1889_CR18","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1053\/j.gastro.2022.06.024","volume":"163","author":"H Chen","year":"2022","unstructured":"Chen H, et al. METTL3 inhibits antitumor immunity by targeting m(6)A-BHLHE41-CXCL1\/CXCR2 axis to promote colorectal cancer. Gastroenterology. 2022;163(4):891\u2013907.","journal-title":"Gastroenterology"},{"issue":"7","key":"1889_CR19","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1111\/jcmm.15033","volume":"24","author":"D Zhang","year":"2020","unstructured":"Zhang D, et al. BHLHE41 suppresses MCF-7 cell invasion via MAPK\/JNK pathway. J Cell Mol Med. 2020;24(7):4001\u201310.","journal-title":"J Cell Mol Med"},{"issue":"8","key":"1889_CR20","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1158\/1538-7445.AM2016-1741","volume":"6","author":"P Li","year":"2016","unstructured":"Li P, et al. DEC2 suppresses tumor proliferation and metastasis by regulating ERK\/NF-\u03baB pathway in gastric cancer. Am J Cancer Res. 2016;6(8):1741\u201357.","journal-title":"Am J Cancer Res"},{"key":"1889_CR21","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1186\/1471-2407-14-487","volume":"14","author":"Y Liao","year":"2014","unstructured":"Liao Y, et al. Suppression of the epithelial-mesenchymal transition by SHARP1 is linked to the NOTCH1 signaling pathway in metastasis of endometrial cancer. BMC Cancer. 2014;14:487.","journal-title":"BMC Cancer"},{"key":"1889_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411731","author":"T Furukawa","year":"2023","unstructured":"Furukawa T, et al. Approach to functions of BHLHE41\/DEC2 in non-small lung cancer development. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241411731.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1889_CR23","first-page":"2137","volume":"41","author":"Z Shen","year":"2019","unstructured":"Shen Z, et al. Overexpression of BHLHE41, correlated with DNA hypomethylation in 3\u2019UTR region, promotes the growth of human clear cell renal cell carcinoma. Oncol Rep. 2019;41(4):2137\u201347.","journal-title":"Oncol Rep"},{"issue":"10","key":"1889_CR24","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1158\/1541-7786.MCR-20-1029","volume":"20","author":"PV Iyengar","year":"2022","unstructured":"Iyengar PV, et al. TRAF4 inhibits bladder cancer progression by promoting BMP\/SMAD signaling. Mol Cancer Res. 2022;20(10):1516\u201331.","journal-title":"Mol Cancer Res"},{"issue":"2","key":"1889_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10863-021-09887-3","volume":"53","author":"S Du","year":"2021","unstructured":"Du S, et al. PYCR1 promotes bladder cancer by affecting the Akt\/Wnt\/\u03b2-catenin signaling. J Bioenerg Biomembr. 2021;53(2):247\u201358.","journal-title":"J Bioenerg Biomembr"},{"issue":"4","key":"1889_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagrm.2023.194979","volume":"1866","author":"G Dagar","year":"2023","unstructured":"Dagar G, et al. Ubiquitination and deubiquitination: implications on cancer therapy. Biochim Biophys Acta Gene Regul Mech. 2023;1866(4): 194979.","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"issue":"2","key":"1889_CR27","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41418-020-00708-5","volume":"28","author":"PE Cockram","year":"2021","unstructured":"Cockram PE, et al. Ubiquitination in the regulation of inflammatory cell death and cancer. Cell Death Differ. 2021;28(2):591\u2013605.","journal-title":"Cell Death Differ"},{"issue":"6","key":"1889_CR28","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.7150\/ijbs.69411","volume":"18","author":"S Han","year":"2022","unstructured":"Han S, et al. The role of ubiquitination and deubiquitination in tumor invasion and metastasis. Int J Biol Sci. 2022;18(6):2292\u2013303.","journal-title":"Int J Biol Sci"},{"issue":"5","key":"1889_CR29","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/s41580-021-00448-5","volume":"23","author":"DA Cruz Walma","year":"2022","unstructured":"Cruz Walma DA, et al. Ubiquitin ligases: guardians of mammalian development. Nat Rev Mol Cell Biol. 2022;23(5):350\u201367.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"1889_CR30","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41418-020-00648-0","volume":"28","author":"F Dang","year":"2021","unstructured":"Dang F, Nie L, Wei W. Ubiquitin signaling in cell cycle control and tumorigenesis. Cell Death Differ. 2021;28(2):427\u201338.","journal-title":"Cell Death Differ"},{"issue":"8","key":"1889_CR31","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.molmed.2023.05.006","volume":"29","author":"D Han","year":"2023","unstructured":"Han D, et al. The ubiquitin-proteasome system in breast cancer. Trends Mol Med. 2023;29(8):599\u2013621.","journal-title":"Trends Mol Med"},{"issue":"3","key":"1889_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1204","volume":"13","author":"C Sampson","year":"2023","unstructured":"Sampson C, et al. The roles of E3 ubiquitin ligases in cancer progression and targeted therapy. Clin Transl Med. 2023;13(3): e1204.","journal-title":"Clin Transl Med"},{"key":"1889_CR33","doi-asserted-by":"publisher","first-page":"1226057","DOI":"10.3389\/fimmu.2023.1226057","volume":"14","author":"M Wang","year":"2023","unstructured":"Wang M, et al. E3 ubiquitin ligases and deubiquitinases in bladder cancer tumorigenesis and implications for immunotherapies. Front Immunol. 2023;14:1226057.","journal-title":"Front Immunol"},{"issue":"1","key":"1889_CR34","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s13046-021-01935-5","volume":"40","author":"Q Wu","year":"2021","unstructured":"Wu Q, et al. ROC1 promotes the malignant progression of bladder cancer by regulating p-I\u03baB\u03b1\/NF-\u03baB signaling. J Exp Clin Cancer Res. 2021;40(1):158.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"1889_CR35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s12276-021-00663-2","volume":"54","author":"M Mao","year":"2022","unstructured":"Mao M, et al. Oncogenic E3 ubiquitin ligase NEDD4 binds to KLF8 and regulates the microRNA-132\/NRF2 axis in bladder cancer. Exp Mol Med. 2022;54(1):47\u201360.","journal-title":"Exp Mol Med"},{"key":"1889_CR36","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.canlet.2018.07.036","volume":"435","author":"WS Wei","year":"2018","unstructured":"Wei WS, et al. TRIM65 supports bladder urothelial carcinoma cell aggressiveness by promoting ANXA2 ubiquitination and degradation. Cancer Lett. 2018;435:10\u201322.","journal-title":"Cancer Lett"},{"issue":"1","key":"1889_CR37","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1186\/s12967-021-03173-x","volume":"19","author":"X Wang","year":"2021","unstructured":"Wang X, et al. TRIM38 triggers the uniquitination and degradation of glucose transporter type 1 (GLUT1) to restrict tumor progression in bladder cancer. J Transl Med. 2021;19(1):508.","journal-title":"J Transl Med"},{"issue":"3","key":"1889_CR38","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41419-021-03521-1","volume":"12","author":"H Xu","year":"2021","unstructured":"Xu H, et al. E3 ubiquitin ligase RNF126 affects bladder cancer progression through regulation of PTEN stability. Cell Death Dis. 2021;12(3):239.","journal-title":"Cell Death Dis"},{"key":"1889_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13132308","author":"M Ferro","year":"2023","unstructured":"Ferro M, et al. Artificial intelligence in the advanced diagnosis of bladder cancer-comprehensive literature review and future advancement. Diagnostics. 2023. https:\/\/doi.org\/10.3390\/diagnostics13132308.","journal-title":"Diagnostics"},{"issue":"10","key":"1889_CR40","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1038\/labinvest.2010.133","volume":"90","author":"CB Ching","year":"2010","unstructured":"Ching CB, Hansel DE. Expanding therapeutic targets in bladder cancer: the PI3K\/Akt\/mTOR pathway. Lab Invest. 2010;90(10):1406\u201314.","journal-title":"Lab Invest"},{"key":"1889_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2014.06.004","volume":"145","author":"N Hou\u00e9d\u00e9","year":"2015","unstructured":"Hou\u00e9d\u00e9 N, Pourquier P. Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment of bladder cancers. Pharmacol Ther. 2015;145:1\u201318.","journal-title":"Pharmacol Ther"},{"issue":"6","key":"1889_CR42","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s42255-022-00582-0","volume":"4","author":"EJ Kay","year":"2022","unstructured":"Kay EJ, et al. Cancer-associated fibroblasts require proline synthesis by PYCR1 for the deposition of pro-tumorigenic extracellular matrix. Nat Metab. 2022;4(6):693\u2013710.","journal-title":"Nat Metab"},{"key":"1889_CR43","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3389\/fonc.2020.00776","volume":"10","author":"C D'Aniello","year":"2020","unstructured":"D\u2019Aniello C, et al. Proline metabolism in Tumor growth and metastatic progression. Front Oncol. 2020;10:776.","journal-title":"Front Oncol"},{"issue":"5","key":"1889_CR44","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/mc.23174","volume":"59","author":"Y Gao","year":"2020","unstructured":"Gao Y, et al. PYCR1 knockdown inhibits the proliferation, migration, and invasion by affecting JAK\/STAT signaling pathway in lung adenocarcinoma. Mol Carcinog. 2020;59(5):503\u201311.","journal-title":"Mol Carcinog"},{"issue":"7407","key":"1889_CR45","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nature11207","volume":"487","author":"M Montagner","year":"2012","unstructured":"Montagner M, et al. SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature. 2012;487(7407):380\u20134.","journal-title":"Nature"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-024-01889-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-024-01889-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-024-01889-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T04:05:34Z","timestamp":1716955534000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-024-01889-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,29]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1889"],"URL":"https:\/\/doi.org\/10.1186\/s40001-024-01889-2","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,29]]},"assertion":[{"value":"28 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants were reviewed and approved by the Research Ethics Committee of Hunan Provincial People\u2019s Hospital. The written informed consent was obtained from each patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"302"}}